Table 1 Demographic characteristics of patients
From: Concomitant 177Lu-DOTATATE and capecitabine therapy in malignant paragangliomas
Characteristics | Value |
|---|---|
Age (years) (mean ± SD; range) | 35.6 ± 11.5 (14–65) |
Gender | |
Male | 19 (76%) |
Female | 6 (24%) |
Metastases | |
None | 5 (20%) |
Lymph nodes | 13 (52%) |
Skeletal | 13 (52%) |
Liver | 3 (12%) |
Lungs | 3 (12%) |
Prior treatment | |
Yes | 19 (76%) |
No | 6 (24%) |
Type of prior therapies | |
Surgery | 14 (56%) |
Chemotherapy | 5 (20%) |
Radiotherapy | 4 (16%) |
131I-MIBG therapy | 2 (8%) |
Inoperable/no treatment affected | 6 (24%) |
Disease status at baseline | |
Progressive disease | 21 (84%) |
Stable disease | 4 (16%) |
Anti-hypertensive drugs | 14 (56%) |
Number of 177Lu-DOTATATE therapy cycles (median, range) | 3 (2–8) |
Treatment duration | |
Median (range) | 30 (15–96) |
Cumulative activity (GBq) | 22.86 ± 9.54 (14.43–50) |